Credit Suisse maintained Eli Lilly (NYSE: LLY ) with an Outperform rating and raised the price target from $65.00 to $68.00. Credit Suisse noted, "We have raised our long-term forecasts for Alimta ex US revenues on higher confidence that the EU patent should hold until 2020 (from current assumption